Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis
about
Molecular Imaging of Angiogenesis and Vascular Remodeling in Cardiovascular PathologyContact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug deliveryImaging and nanomedicine in inflammatory atherosclerosisMolecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agentsPrevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound.Recent Advances in (19)Fluorine Magnetic Resonance Imaging with Perfluorocarbon Emulsions.Assessing the barriers to image-guided drug delivery.Perfluorocarbon nanoparticles for physiological and molecular imaging and therapyMolecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance.Perfluorocarbon nanoparticles: evolution of a multimodality and multifunctional imaging agent.Imaging atherosclerosis and vulnerable plaque.Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for drug delivery to cancer.A fibrin-specific thrombolytic nanomedicine approach to acute ischemic strokePerspectives and opportunities for nanomedicine in the management of atherosclerosis.Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsionsRationale for a nanomedicine approach to thrombolytic therapy.Multifunctional agents for concurrent imaging and therapy in cardiovascular diseaseTheragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsionsEmerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases.Plasmonic nanobubbles as tunable cellular probes for cancer theranosticsNanomedicine strategies for molecular targets with MRI and optical imaging.Open access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicineConquering the dark side: colloidal iron oxide nanoparticles.Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects.Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrin-targeted nanoparticles.Magnetic resonance chemical exchange saturation transfer imaging and nanotechnology.Quantitative cardiovascular magnetic resonance for molecular imaging.Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces.Molecular imaging of plaque vulnerability.Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis.alphaVbeta3-targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment.Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers.Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases.Nanomedical Theranostics in Cardiovascular Disease.Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosisMolecular imaging of atherosclerosis for improving diagnostic and therapeutic developmentMR molecular imaging of aortic angiogenesis.Angiogenesis is required for stress fracture healing in rats.Atherosclerotic neovasculature MR imaging with mixed manganese-gadolinium nanocolloids in hyperlipidemic rabbitsMolecular MR imaging of neovascular progression in the Vx2 tumor with αvβ3-targeted paramagnetic nanoparticles
P2860
Q26747500-DB155E23-AF21-4A9C-A5B2-21741F469C48Q26795703-C3217640-B718-4A46-9D56-E831D0936071Q27002916-C6CA8E7F-52BA-46CC-A8FC-A7B03534F265Q27027613-6A085F1C-F93F-41CC-B94C-2F2CA7CCC332Q30357131-1A8FD387-2638-404A-9BFA-D93E41FC102FQ30385272-0876F122-6A89-4C0E-A0A1-6DC2EB431032Q30422169-43774930-889C-4B9D-B034-FE86640F3D33Q30426880-68A0B8D5-65CC-41B8-9FB6-F0306A3A7168Q30434516-C9D8FA31-1E01-49C1-AC3C-6DF3DB9AD33EQ30434964-4DAF287D-1EAB-4693-AA59-58F1E95FCCB7Q30435383-F596DF7D-3058-40AD-8AFF-951C484A0943Q30450131-642F4097-BDA7-4734-B166-34E29034D980Q30452739-3AFFDEFE-355F-4CC9-A2A9-87DA2C3CD638Q30455490-F0F61192-4D2B-4135-A31C-398CBA29CCCCQ30465710-5E126EC3-884E-4E56-AFC0-2ABBF6B93BF7Q30474015-056D6B6E-D9EA-467A-9BC3-D983AB6E0063Q30474418-0A591BBB-94C7-41C8-8830-66BA029B48C5Q30474759-C733A4EE-7F89-4585-B94C-0205D7FB1203Q30475719-DF6C938F-88A9-453E-9DBB-E7B65204DE5EQ30476207-56C8BFCB-1FB7-4D78-B98A-F15EE0646690Q30481471-4EC47124-63CA-4211-9499-87D1EDE0F7F6Q30487537-F7D3FCE0-89B2-48AB-806A-65511D5A227AQ33554945-93FCEB35-64E7-40DA-BDBA-7777BB1B73E0Q34030709-9CB55F7E-CEAB-4FF0-BAF3-6E1F5F4A0F21Q34033191-60AB8713-E89D-4BA8-A698-C193140BE055Q34197669-C5CD111C-4B14-43A6-8956-F94422BD836FQ34330885-F42BFA94-3369-4ADF-9787-C11970DDFA76Q34452451-C1A34F4A-555C-44D1-9E0E-856F80AF8AE3Q34498697-D56B6807-CB14-41B0-B996-7D92E728F171Q34562028-A5D0CE02-8623-4CC4-9FD8-EA593FE2001EQ34785222-71F563CB-4C50-4039-BBB9-338C8DA41654Q35558487-6A342ED4-72F9-4948-AA16-BD4475A3FEC6Q35667247-2EFC044D-F5CA-44F3-82E6-0937E7B8B1C3Q35681183-B456F0A9-A7FF-4EAE-98F5-D31B701BCB74Q35710262-1C0469FF-16A9-4672-9762-A452DAF73D7FQ36141999-F076DF83-E233-4A8A-9BC4-168918B1CFE2Q36182417-72CF3693-68B9-4497-95F5-27B295ED005BQ36442977-8B8B6B16-7BEB-43BF-9F67-2537EAE3375AQ36483514-A6008400-CEF9-430F-B717-8D3D2E200B5EQ37039546-B54489A0-7B8D-4583-BECC-6FFA6A225DCE
P2860
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antiangiogenic synergism of in ...... torvastatin in atherosclerosis
@en
Antiangiogenic synergism of in ...... orvastatin in atherosclerosis.
@nl
type
label
Antiangiogenic synergism of in ...... torvastatin in atherosclerosis
@en
Antiangiogenic synergism of in ...... orvastatin in atherosclerosis.
@nl
prefLabel
Antiangiogenic synergism of in ...... torvastatin in atherosclerosis
@en
Antiangiogenic synergism of in ...... orvastatin in atherosclerosis.
@nl
P2093
P2860
P1476
Antiangiogenic synergism of in ...... torvastatin in atherosclerosis
@en
P2093
Gregory M Lanza
Huiying Zhang
Samuel A Wickline
Shelton D Caruthers
Todd A Williams
P2860
P304
P356
10.1016/J.JCMG.2008.06.003
P577
2008-09-01T00:00:00Z